# EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

> **NCT05093634** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 296 (actual)

## Conditions studied

- Obesity
- Genetic Obesity

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05093634
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-10
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-12-31
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093634, "EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05093634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*